OpenAI Researcher Miles Wang Launches Startup Focused on AI Drug Discovery
Miles Wang, a prominent researcher at OpenAI known for his innovative work in using artificial intelligence to enhance scientific and biological discovery, is making waves by leaving the tech giant. He is set to launch a new startup aimed at developing AI models specifically for drug discovery.
Sources close to the matter indicate that Wang’s new venture could attract around $200 million in funding and is projected to reach a valuation of approximately $2 billion. Notably, Lightspeed Venture Partners is reportedly in discussions to lead this funding round, although final details have yet to be confirmed as negotiations continue.
Funding Figures Under Discussion
While some figures regarding the funding have surfaced, Wang has disputed their accuracy without offering specific corrections. Lightspeed has not commented on these discussions as of yet, leaving many curious about the new project’s financial prospects.
Growing Interest in AI for Life Sciences
The move signifies a rising investor interest in the application of AI within life sciences. For instance, Chai Discovery, a startup focusing on AI models that predict molecular interactions for drug identification, recently announced a remarkable $400 million funding round at a whopping $3.8 billion valuation. Notably, its co-founder, Josh Meier, also has experience at OpenAI. Similarly, Google DeepMind spinout Isomorphic Labs disclosed a $2.1 billion Series B funding in May 2023.
Innovative Approaches to Drug Discovery
Wang’s new company is poised to explore groundbreaking methods in drug discovery. Reports suggest that the startup may focus on AI models designed to uncover new applications for existing medications, including those that previously failed clinical trials. This approach could significantly expedite the pathway to market because the safety of these drugs is already established, potentially streamlining the revenue generation process.
Wang’s Journey from Harvard to OpenAI
Miles Wang began his career in tech by dropping out of Harvard, where he was studying computer science, to join OpenAI in 2024. His decision reflects a shifting trend where investors are increasingly willing to back young founders, even those who have yet to complete their degrees.
During his tenure at OpenAI, Wang contributed to several research papers, highlighting the potential for AI to automate and expedite scientific discovery.
Conclusion: A Bold Move into the Future of Medicine
Miles Wang’s transition from OpenAI to his new startup marks a significant development in the marriage of technology and medicine. As the healthcare sector increasingly leans on AI capabilities, the evolution of Wang’s company could signify not just advancements in drug discovery, but a fresh wave of innovation in life sciences on a broader scale. This promising endeavor is one to watch as it unfolds.
